221 results about "Pantoprazole" patented technology

An oral pharmaceutical composition comprises an acid-labile irreversible proton pump inhibitor in pellet or tablet form, wherein the irreversible proton pump inhibitor is at least partly in slow-release form. On combined administration with an anti-microbially-active ingredient, the composition is distinguished by imparting an enhanced action of rapid onset against disorders caused by Helicobacter.

Pantoprazole sodium multiparticulates are described which avoid sticking to nasogastric and gastronomy tubes. The pantoprazole multiparticulates have a spheroid core of pantoprazole or an enantiomer thereof, or a salt thereof, a surfactant, and a distintegrant; a sub coat which is comprised of hydroxypropyl methylcellulose (hypromellose) and water, an enteric coat on the sub-coat, and a final seal coat over the enteric coat, which is composed of hydroxypropyl methylcellulose (hypromellose) and water.

The invention relates to a method for preparing batoracosodium freeze dried, whose pH value is 9.5-11.5. And the invention comprises 1 deal of batoracosodium, 0.5-1 deals of supporting agent, 0-0.06 deals of weak-acid strong-alkali salt, and some inorganic alkali. And the preparation comprises that 1, preparing materials; 2, dissolving the supporting agent and weak-acid strong-alkali salt via injection water, using inorganic salt to adjust the pH value to 9.5-11.5, adding batoracosodium, dissolving and using inorganic salt to adjust the pH value to 9.5-11.5; 3, filtering; 4, freezing and drying to obtain the final product. The invention can be used treat peptic ulcer, ulcer bleed, or the like.

The invention discloses a pantoprazole sodium enteric-coated pellet which contains the following components in percentage by weight from inside to outside: 20-60 percent of blank core pellet, 4-38 percent of medicinal layer containing pantoprazole sodium and one or more medicinal excipients, 2-15 percent of isolated layer and 15-26 percent of enteric-coated layer. The invention also discloses a preparation method and an application of the enteric-coated pantoprazole sodium pellet. The pantoprazole sodium enteric-coated capsule has the advantages of better stability, uniform absorption, smaller difference of bioavailability among individuals, and the like.

Novel crystalline forms of pantoprazole sodium salt solvate with ketone solvents, a process for the preparation thereof, the use of the forms for the purification of pantoprazol, pharmaceutical compositions therefrom and the use thereof in therapy.

The invention provides a preparation method of pantoprazole sodium. The method comprises the following steps of: 1) generating 2-chloromethyl-3,4-dimethoxypyridine hydrochloride (III) by taking 2-hydroxymethyl-3,4-dimethoxypyridine (II) as the start raw material in the presence of chloride; 2) condensing the obtained compound (III) with 5-difluoromethoxy-2-sulfydryl-1H-benzimidazole in alkaline conditions in the presence of inorganic base to generate 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridyl)methyl]thioxo-1H-benzimidazole (IV); and 3) salifying the obtained compound (IV) with sodium hydroxide, and oxidizing with an oxidizing agent to generate 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl-1H-benzimidazole sodium, namely pantoprazole sodium (I). According to the invention, the operation is simple and efficient, the reaction conditions are mild, the safety is high, the control is easy, the yield is relatively high, and the method is suitable for industrial production.

The invention relates to pantoprazole sodium and a preparation method thereof and in particular relates to a method for preparing the pantoprazole sodium. The preparation method comprises the following steps of: (1) with 2-hydroxymethyl-3,4-dimethoxyl pyridine (II) as a starting material, generating 2-chloromethyl-3,4-dimethoxyl pyridine hydrochloride (III) under the action of chlorides; (2) carrying out condensation on the obtained compound (III) and 5-difluoromethoxyl-2-sulfydryl-1H-benzimidazole in the presence of inorganic base to generate 5-difluoromethoxyl-2-[(3,4-dimethoxyl-2-pyridyl) methyl] sulfenyl-1H-benzimidazole (IV); (3) oxidizing the obtained compound (IV) by using an oxidant to generate 5-difluoromethoxyl-2-[(3,4-dimethoxyl-2-pyridyl) methyl] sulfinyl-1H-benzimidazole; (4) enabling the 5-difluoromethoxyl-2-[(3,4-dimethoxyl-2-pyridyl) methyl] sulfinyl-1H-benzimidazole to react with sodium hydroxide to generate a salt, namely the pantoprazole sodium (I); and optionally (5) refining the prepared pantoprazole sodium. According to the preparation method, the prepared pantoprazole sodium product has high purity.

The invention provides a pantoprazole sodium composition for injection. The composition contains pantoprazole sodium and disodium ethylene diamine tetraacetate that are in a proportion of 1:0.02-0.1 by weight. And the composition is prepared by the steps of: 1) liquid medicine preparation: placing pantoprazole sodium and disodium ethylene diamine tetraacetate in a preparation pot, adding water for injection and stirring to make the above agents dissolved and mixed well with the water, adjusting the pH value of the mixture to 10.5-12.5; 2) rubber stopper treatment; 3) aseptic filtration and separate packing; 4) vacuum freeze drying, thus obtaining the composition. For pantoprazole sodium medicaments extremely easy to react with exudates from a rubber stopper, the pantoprazole sodium composition for injection in the invention can simultaneously guarantee the visible foreign matters and insoluble particles in products meeting the requirement of an injection. According to the invention, quality level of the composition product is improved, and the hidden trouble that unqualified visible foreign matters and insoluble particles threat patient clinical medication safety can be avoided. Additionally, the composition of the invention has better curative effects and less clinical side effects.

The invention provides a sub-micro emulsion frozen preparation of pantoprazole sodium and a preparation method thereof. The sub-micro emulsion frozen preparation of pantoprazole sodium is prepared mainly with the following components according to portions by weight: 1-10 portions of pantoprazole sodium, 5-50 portions of biodegradable polymer, 1-20 portions of emulsifying agent, 5-40 portions of skeleton supporting agent and 1-20 portions of stabilizing agent.